Table 1 Patient information for the study.

From: Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding

Patient no

Age

Sex

Type of APS

Thrombotic events

Pregnancy morbidity

LA-positive

aCL

Anti-beta2GPI

Anti-DI

1

53

Male

PAPS

1 Arterial

Not applicable

Yes

 > 100

86

26

2

57

Female

SLE Associated

Multiple Venous

One termination of pregnancy for medical reasons

Yes

 > 100

85

89

3

74

Male

PAPS

Multiple Venous and Arterial

Not applicable

Yes

 > 100

 > 100

 > 100

4

37

Female

SLE Associated

1 Arterial

One first trimester loss, one premature delivery 29/52 due to placental thrombosis

Yes

 > 100

 > 100

 > 100

  1. Demographic and clinical characteristics, as well as antibody levels are given.
  2. PAPS primary antiphospholipid syndrome, SLE systemic lupus erythematosus, LA lupus anticoagulant, aCL anti cardiolipin antibodies.
  3. Triple positivity (positive tests 12 weeks apart for anti-Cardiolipin (aCL), anti-Beta-2-Glycoprotein I (aβ2GPI) and Lupus Anticoagulant) is associated with a more severe phenotype for APS patients36,37. These polyclonal IgG samples were tested for binding to untreated and reduced β2GPI. Significantly higher binding was seen with reduced protein at all concentrations (Fig. 5A). A dose-dependent response was observed with a maximal concentration of 5 µg/mL reduced β2GPI giving an OD of ~ 1.
Back to article page